In the early 2000s, I was part of a team of researchers and health system decision makers leading a study of public involvement in regionalized health systems across Canada. 1 The study had the slightly longwinded title: Towards more informed, meaningful and effective public consultation. It addressed a comparable topic to the one covered by Rozmovits et al. 2 in their article in this issue, which asks the question 'What does meaningful look like?' in the context of patient engagement in health technology assessment (HTA).
Since embarking on our work in the early 2000s, the field of public, and now patient, engagement has grown exponentially. Its roots can be traced back much further, and to numerous contributing disciplines and fields, but the last decade, in particular, has witnessed unprecedented attention to a more transformative role for patients in the domains of health research and health systems and policy decision making. A preoccupation within the field has been the determination of how to 'meaningfully' engage patients, suggesting a desire to move away from less meaningful practices that have characterized prior efforts, or a need to ensure that the approaches taken will add value to the process and to the parties involved. This concern has also been shared within the HTA field where efforts to involve the public and patients have been accompanied by a growing number of systematic reviews, conceptual frameworks, surveys of the field, stakeholder perspectives and case studies. [3] [4] [5] [6] [7] [8] [9] [10] [11] Rozmovits et al.'s paper contributes another offering to the field, this time through the lens of participants in the process for reviewing and providing guidance for the funding of oncology drugs in Canada, known as the pan-Canadian Oncology Drug Review (pCODR). The perspectives explored are those of members of the various committees and advisory groups that contribute to the pCODR process. They were asked to consider the purpose and value added of patient engagement, the strengths, weaknesses and impacts of submissions from patient advocacy groups, and what an "optimized patient engagement" process might look like. The paper's key message centres on what the authors describe as a 'misalignment of stakeholder expectations' which presents challenges for patient engagement efforts in the future.
The authors' results are presented clearly and succinctly. Several of them point to more subtle messages and complexities that are explored in the sections below. These include the way in which patient engagement is defined and assessed in studies of these types, the need to disentangle the role of advocacy groups as organized interests vs. representatives of patient values and experience, and what might be needed to make further progress towards the authors' notion of 'optimized patient engagement'.
Patient engagement defined and assessed: broad versus narrow
While not evident from the title, the focus of Rozmovits et al.'s paper is on a very specific stage within the pCODR process, the patient submission process. In this stage, patient advocacy groups are invited to make submissions on drugs under review and to provide patient and caregiver perspectives on the experience of living with a given disease and on currently available treatments, which inform comparisons between new and existing treatments. While often viewed as a form of patient engagement, by most accounts, patient submissions are fairly passive. They involve a structured consultation where information is requested from patients on a range of topics, usually predetermined by the HTA organization. While an important input to the pCODR process, assessing a patient submission process in terms of its meaningfulness is quite different from assessing whether meaningful patient engagement has been achieved, either within the pCODR process itself, or within the Canadian Agency for Drugs and Technologies in Health, the larger organization within which pCODR now resides. The paper reveals important strengths and weaknesses about the current patient submission process at pCODR, but there are limits to what can be learned from this study in relation to broader questions about what constitutes meaningful patient engagement and how this might be assessed.
Disentangling the roles of patient advocacy groups in patient engagement
Given the article's primary focus on what constitutes a meaningful submission process (and what does not), we come to the second theme for further exploration, disentangling the roles of patient advocacy groups in patient engagement. The paper presents a list of attributes viewed by study participants as 'detracting from meaningful patient engagement'. Among these are 'emotional appeals perceived as lacking credibility' and 'conflating participation in HTA with other functions of patient advocacy groups. . .' Related concerns are the 'lack of relevance' of these emotional appeals, a misunderstanding of 'what kind of information should be included in the patient submission process' and 'insufficient information [being] provided about how the submission was prepared'. These critiques convey a tone of disappointment at not getting 'the right' information from patients' groups in the 'right' format. Further, they suggest a role for advocacy group members as information sources for HTA that can be disconnected from their interests in shaping the outcome of related policy processes. The authors summarize the situation by highlighting a 'fundamental tension between the evidence-based nature of HTA and the experientially-oriented culture of patient advocacy'. Whether and how this tension can be resolved is an important question.
It should come as no surprise that representatives of patient advocacy groups will seek to do just that, advocate on behalf of those whose interests they are seeking to advance. We may not agree with the interests that are being advanced or how this should be done, but being naı¨ve to the goals of these organizations serves no useful purpose. As such, structuring a patient submission process based on soliciting input from advocacy groups, let alone those representing the interests of cancer patients, is a tricky business. How do we determine which emotional appeals are credible and which are not? And whose role is it to make this assessment? This may be an unrealistic aim and even contradictory to the goal of understanding patients' lived experience. 
Towards optimal patient engagement
One of the outputs of the research we carried out more than 15 years ago (published in 2004 in this Journal) 12 was a set of citizen perspectives that could be used to inform methods and models for public involvement, who better to consider how to do this well than those we are seeking to engage! Rozmovits et al. wisely plan to seek the perspectives of patient advocacy groups as a next step to their work and cite recent work which has done the same. 10,11 A key message from these studies is the importance of clarity of communication about the purpose of the patient submission or broader engagement process and about what is expected from each group. This means getting the information and communication principles right, a no-brainer to most of us, but one that requires careful attention, time and effort.
Attending to these core procedural elements will certainly help achieve the goal of optimal patient engagement, but there are other key requirements. First and foremost is the need to establish a clear vision for patient engagement at the organizational level, not simply within discrete engagement processes but across the entire pathway of HTA and management activities. 9 Patient engagement needs to be viewed through a broader lens than through its component parts. This includes an understanding of the history and culture of the HTA organization or process, how patient engagement is understood and viewed within it, and by all stakeholders, from the organizational leadership to the staff supporting it, in addition to those directly participating in its activities. It is only through a holistic and multidisciplinary approach to patient engagement that efforts to achieve meaning from it will be successful.
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